Custom peptide synthesis: difference between revisions
Diff·revision 13 → 14·13:42, 19 May 2025
Difference between revision 13 and revision 14 of Custom peptide synthesis. 6 lines changed; the page grew by 735 bytes.
| Revision 13 — 03:15, 29 Apr 2025 SarcopeniaSefa (talk) move a stray full stop inside the reference 3,777 bytes ±0 | Revision 14 — 13:42, 19 May 2025 DPP4_Dagmar (talk) add the excursion tolerance with the study it derives from 4,512 bytes +735 | ||
|---|---|---|---|
| 34 | Quotations for sequences corresponding to compounds under patent, or to controlled substances, raise separate questions that are legal rather than technical. This wiki does not advise on them; see [[Regulatory status by jurisdiction]] and [[Patent expiry and biosimilars]].{{r|iso9001}} | 34 | Quotations for sequences corresponding to compounds under patent, or to controlled substances, raise separate questions that are legal rather than technical. This wiki does not advise on them; see [[Regulatory status by jurisdiction]] and [[Patent expiry and biosimilars]].{{r|iso9001}} |
| 35 | 35 | ||
| + | 36 | == Documentation for custom work == | |
| + | 37 | Custom work more often carries fuller documentation than catalogue supply, because the specification was negotiated. Certificates from custom orders in submissions to this wiki more often include [[Mass spectrometry|mass confirmation]], [[Amino acid analysis|amino acid analysis]] and an itemised related-substances table than catalogue certificates do.{{r|reports}} | |
| + | 38 | ||
| + | 39 | That is an observation about a self-selected set of submitted documents rather than a general finding about the market, and it should not be read as a comparison between named organisations. | |
| + | 40 | ||
| 36 | == References == | 41 | == References == |
| 37 | {{reflist}} | 42 | {{reflist}} |
| ⋮ | ⋮ | ||
| 39 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 44 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 40 | <ref name="iso9001">ISO 9001:2015, ''Quality management systems — Requirements''.</ref> | 45 | <ref name="iso9001">ISO 9001:2015, ''Quality management systems — Requirements''.</ref> |
| + | 46 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 41 | 47 | ||
| 42 | == See also == | 48 | == See also == |